Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2011. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 1,500,000 ordinary shares of 25 pence each.
- Transaction Date: June 21, 2011.
- Price Range: Highest price paid was 1,282 pence per share; lowest price paid was 1,272.5 pence per share.
Material Changes
Following the cancellation of the repurchased shares, the company's treasury holdings and capital structure were updated as follows:
- Treasury Shares: GSK now holds 499,174,284 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.84% of total issued share capital and 9.70% of total voting rights.
- Shares in Issue: There are 5,144,693,633 shares in issue (excluding Treasury shares), which represents the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the updated total voting rights denominator (5,144,693,633 shares) for disclosure threshold calculations under FSA rules.
- Confirm the impact of the 1,500,000 share cancellation on the company's total issued share capital.
- Note that this filing does not contain operational or financial performance data for the period; refer to Form 20-F for full financial results.